Hypothesis

Aged hematopoietic stem cells (HSCs) release mitochondria‑derived oxidative extracellular vesicles that transfer oxidized mtDNA to peripheral tissues, where it activates the cGAS‑STING pathway and drives a secondary wave of senescence independent of immune cell senescence. This positions mitochondrial ROS in HSCs as an upstream initiator of inflammaging, suggesting that rescuing HSC mitochondrial fidelity will attenuate both myeloid skewing and distal tissue aging more effectively than targeting senescent immune cells alone.

Mechanistic Rationale

Age‑associated DNA damage and mTOR hyperactivation in HSCs increase mitochondrial ROS production [1, 2]. Elevated ROS oxidizes mitochondrial DNA and promotes its packaging into exosomes that are released into circulation. Oxidized mtDNA is a potent agonist of cytosolic cGAS, triggering STING‑dependent IFN‑β production and NF‑κB activation in stromal cells [3]. The resulting paracrine SASP amplifies senescence in fibroblasts, endothelial cells and parenchyma, creating a feed‑forward loop that reinforces HSC myeloid bias via inflammatory cytokines feeding back on the marrow niche [4]. Thus, immune aging is not merely a consequence of senescence but is sparked by a mitochondrial signal that precedes lymphoid decline.

Testable Predictions

1. In aged mice, intravenous injection of mitochondria‑targeted antioxidant MitoQ will reduce circulating oxidized mtDNA‑containing exosomes by >40% within two weeks [5].
2. Parallel to exosome reduction, serum IL‑6 and TNF‑α will drop proportionally, and the proportion of Ly6C^hi inflammatory monocytes in bone marrow will fall from ~35% to <20%.
3. Epigenetic clocks measured in liver and muscle will show a delay of ~0.25 methylation years relative to untreated controls, indicating slowed systemic aging.
4. Adoptive transfer of HSCs from MitoQ‑treated donors into irradiated young recipients will confer resistance to myeloid skewing and lower tissue senescence markers compared with transfer of untreated HSCs.

Potential Falsification

If MitoQ treatment fails to lower oxidized mtDNA exosomes, does not change myeloid skewing, or does not alter epigenetic age in distal tissues despite adequate drug exposure, the hypothesis that HSC‑derived mitochondrial ROS drives inflammaging will be refuted. Likewise, if neutralizing cGAS‑STING in stromal cells abolishes the senescence spread without affecting HSC mitochondria, the causal direction would need revision.

Implications for Biohackers

Monitoring plasma ketone β‑hydroxybutyrate (≥0.5 mM) and HOMA‑IR (<1.5) alongside a novel biomarker—circulating oxidized mtDNA exosome concentration—could reveal whether metabolic interventions are hitting the proposed upstream node. A sustained decrease in this exosome readout would predict subsequent improvements in immune phenotype and epigenetic age.